Sarah Oliai

Cooley advised Jiangsu Hengrui Pharmaceuticals, one of the largest pharmaceutical companies in China, on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco, a newly established Delaware company.

Cooley advised Cache DNA, a life sciences company revolutionizing biological sample and data storage infrastructure, on the close of its seed round.

Cooley advised Community, a short message service (SMS) customer engagement platform that connects businesses, brands, political and public figures, creators, musicians, celebrities and more, on its $25 million Series B financing. Partner Dave Young led the Cooley team.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its $112 million oversubscribed Series B financing.

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.